NewAmsterdam Pharma (NASDAQ:NAMS) Director James N. Topper Acquires 660 Shares

Key Points

• Director James Topper of NewAmsterdam Pharma purchased 660 shares at an average cost of $23.70, increasing his total ownership to approximately 3.03 million shares.
• The company's stock price recently hit $24.49, with a market cap of $2.76 billion, and it has reported a negative net margin of 259.07%.
• Analysts have given NewAmsterdam Pharma a consensus rating of "Moderate Buy" with a target price of $41.55, indicating optimism about its future performance.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) Director James N. Topper bought 660 shares of the company's stock in a transaction dated Monday, September 15th. The shares were purchased at an average cost of $23.70 per share, with a total value of $15,642.00. Following the acquisition, the director directly owned 3,028,524 shares of the company's stock, valued at approximately $71,776,018.80. This represents a 0.02% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NewAmsterdam Pharma Stock Down 1.0%

Shares of NAMS traded down $0.27 during midday trading on Friday, reaching $26.46. 180,351 shares of the stock were exchanged, compared to its average volume of 886,649. NewAmsterdam Pharma Company N.V. has a twelve month low of $14.06 and a twelve month high of $27.35. The company has a market cap of $2.98 billion, a P/E ratio of -16.33 and a beta of -0.01. The stock's 50 day simple moving average is $24.00 and its 200 day simple moving average is $20.93.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.37. The business had revenue of $19.15 million during the quarter, compared to the consensus estimate of $1.44 million. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%. As a group, analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of institutional investors have recently modified their holdings of NAMS. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of NewAmsterdam Pharma by 19.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock valued at $80,000 after purchasing an additional 596 shares in the last quarter. Northern Trust Corp purchased a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth about $556,000. Arizona State Retirement System purchased a new position in NewAmsterdam Pharma during the 1st quarter valued at approximately $215,000. PTM Wealth Management LLC purchased a new position in NewAmsterdam Pharma during the 2nd quarter valued at approximately $256,000. Finally, California State Teachers Retirement System lifted its stake in shares of NewAmsterdam Pharma by 23.5% in the 4th quarter. California State Teachers Retirement System now owns 19,404 shares of the company's stock valued at $499,000 after purchasing an additional 3,694 shares during the last quarter. 89.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on NAMS shares. Needham & Company LLC reiterated a "buy" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, June 12th. The Goldman Sachs Group started coverage on NewAmsterdam Pharma in a research report on Thursday, July 17th. They issued a "neutral" rating and a $27.00 target price on the stock. Citigroup started coverage on NewAmsterdam Pharma in a research report on Tuesday, June 17th. They issued a "buy" rating and a $42.00 target price on the stock. Cantor Fitzgerald started coverage on NewAmsterdam Pharma in a research report on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 target price on the stock. Finally, Wells Fargo & Company began coverage on NewAmsterdam Pharma in a research report on Monday, August 25th. They issued an "overweight" rating and a $45.00 target price on the stock. Nine research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, NewAmsterdam Pharma presently has an average rating of "Moderate Buy" and a consensus target price of $41.55.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.